RIPK3 and Alzheimer disease: Consistent with the previous report in AD patients, RIPK3 expression levels were not significantly different between AppNL-G-F and WT rats either at 6-month (Supplementary information, Fig. S9a, d) or 12-month of age (Fig. 6d, g), but not at 3-month of age (Supplementary information, Fig. S9e–g).